Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years

Discover three megatrend stocks positioned for the next decade of growth as AI, healthcare innovation, and clean energy reshape the global economy

MarketBeat

5 Stocks To Keep an Eye On in 2026, According to Experts

Healthcare, retail and finance stocks could do well in 2026. See five picks that experts say could have major upside potential. Find out more right now.

GOBankingRates

As Jensen Huang Preps to Visit China, How Should You Play Nvidia Stock?

Nvidia is a tech stock that has outpaced the broader markets by a significant margin over the past decade. Is NVDA still a good buy as Jensen Huang prepares to visit China?

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Barchart

People who stop using Mounjaro suffer reversal of health benefits, says study

Ceasing use of jabs brings regained weight plus loss of benefits regarding ‘bad’ cholesterol and blood pressure

The Guardian - UK

Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

Benzinga

Mounjaro manufacturer blasts UK as ‘worst country in Europe’ for drug prices

The boss of Eli Lilly, Dave Ricks, warns that Britain will miss out on new drugs as a result of pricing issues

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

From the Beatles to biologics – how Liverpool became a life science hotspot

The city has a long history with tropical medicine and is now home to one of the largest biotech clusters in Europe

The Guardian - UK

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

Evening Standard

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

The Independent UK

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Kiplinger

Kimiko Hahn wins $100,000 award from Poetry Foundation for lifetime achievement

Cornelius Eady, Toi Derricotte and Kimiko Hahn are among this year’s winners of awards from the Poetry Foundation, which announced some of poetry's most lucrative prizes

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.